Cargando...
Effect of Vicriviroc on the QT/Corrected QT Interval and Central Nervous System in Healthy Subjects
Vicriviroc is a CCR5 antagonist in clinical development for the treatment of HIV-1. Two phase I studies were conducted to assess the safety of vicriviroc. One study characterized the drug's potential to prolong the QT/corrected QT (QTc) interval and to induce arrhythmia. In this partially blind...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society for Microbiology (ASM)
2010
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2876383/ https://ncbi.nlm.nih.gov/pubmed/20350942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01447-09 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|